GHH.L

Gooch & Housego Plc
Gooch & Housego PLC - Full Year Trading Update
8th October 2024, 06:00
TwitterFacebookLinkedIn
To continue viewing RNS, please confirm that you are a Private Investor*

* A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:

  1. Obtains access to the information in a personal capacity;
  2. Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
  3. Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
  4. Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
  5. Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
  6. Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
RNS Number : 2450H
Gooch & Housego PLC
08 October 2024
 

 

 

8 October 2024

 

Gooch & Housego PLC

("G&H" or the "Company" or the "Group")

 

Full Year Trading Update

and

Notice of Results

 

 

Gooch & Housego PLC (AIM: GHH), the specialist manufacturer of photonic components & systems, announces its trading update for the financial year ended 30 September 2024. Trading in the second half of the financial year has been strong compared with the first half and is in line with current market expectations.

 

Trading Update

 

The Group is pleased to report that, as expected, trading levels improved during the second half of the year.

 

In our Industrial markets, volumes of our fibre optic modules and assemblies used in both advanced lithography systems and subsea data networks grew in the second half compared with the first half of the year, as programmes migrated to volume production. However, revenues from our industrial laser customers remained broadly flat compared with the first half of the year. Whilst there are early signs of a pick-up in demand, we expect a sustained recovery from our broader industrial laser and semiconductor markets in the second half of the coming calendar year.

 

In our Aerospace and Defence business there was second half revenue growth from deliveries of precision optics and advanced sighting systems into both air and land miliary platform programmes. In the commercial aerospace market demand for our ring laser gyro components continues to be strong and we are now benefiting from the additional capacity we have added to meet  increasing demand.

 

Volumes from our Ashford facility for medical diagnostic instruments increased in the second half of the year owing to the phasing of customers' programmes.  Our Life Sciences R&D team remains fully engaged in supporting customers with the design and accreditation of their next generation instruments which are expected to convert to production revenues for the Group in the coming years. Deliveries into our medical laser customers saw some recovery in the second half as the prolonged destocking cycle that we have experienced is ending.  

 

Thanks to the stronger trading performance in the second half the Board expects the Group to deliver full year revenue and adjusted pre-tax profit in line with current market expectations.



 

Cash

Cash generation in the second half of the financial year has been good and the Group has been able to reduce its borrowing by $3.9m. Net debt (pre-IFRS 16) at the financial year end is, therefore, expected to be slightly better than market expectations.

Outlook

As at 30 September 2024 the Group's order book stood at £104.5m (30 September 2023: £115.3m after adjusting for the divestment of the EM4 business). On an organic constant currency basis the order book declined by 5% during FY2024, partially due to a further £1.4m reduction in the Group's past due backlog and from the timing of orders for our medical diagnostic instruments. Our order book for medical laser devices has also declined but we are now starting to see evidence of the start of a recovery from this market.  In our industrial markets, whilst the destocking patterns we saw in the first half of the year are now behind us, we have not yet seen sustained recovery in the industrial laser market.

 

Offsetting these declines our Aerospace and Defence order book has grown strongly in the financial year thanks to increased demand from both our commercial and defence customers assisted by the enhanced value proposition we are able to offer. Our teams in the UK and US are focused on converting a healthy pipeline of new Aerospace and Defence prospects.

Notice of Results

The Company will announce its audited results for the year ended 30 September 2024 on 3 December 2024.

 

Charlie Peppiatt, Chief Executive Officer of Gooch and Housego, commented:

"Following the first half result, the Group recovered well in the second half to deliver the expected increase in output.

"Whilst we do not expect to see our industrial laser and semi-conductor markets return to growth until next year, we are seeing strong demand for our advanced optical systems capabilities from the defence sector and there are significant new business opportunities that we are working hard to secure.

"We continue to make progress on delivering the self-help, technology and portfolio activities that underpin our strategic plan. We saw further improvement with on time delivery performance in FY2024 and customer feedback is now trending in a positive direction.

"The Group is now better positioned to benefit from the anticipated sustained recovery from our end markets next year thanks to the disciplined implementation of our strategy."

 



 

For further information please contact:

 

Charlie Peppiatt, Chief Executive Officer

Chris Jewell, Chief Financial Officer 

Gooch & Housego PLC

+44 (0) 1460 256440


 


Mark Court / Sophie Wills/ Abigail Gilchrist

G&H@buchanan.uk.com

Burson Buchanan

+44 (0) 20 7466 5000


 


Christopher Baird / David Anderson

Investec Bank plc

+44 (0) 20 7597 5970

 

 

Notes to editors

 

1.     Gooch & Housego is a photonics technology business headquartered in Ilminster, Somerset, UK with operations in the USA and Europe. A world leader in its field, the company researches, designs, engineers and manufactures advanced photonic systems, components and instrumentation for applications in the Aerospace & Defence, Industrial, Life Sciences and Scientific Research sectors. World leading design, development and manufacturing expertise is offered across a broad range of complementary technologies.

 

2.     All financial information included in this announcement is sourced from unaudited management accounts and excludes any specific items. This announcement contains certain forward-looking statements that are based on management's current expectations or beliefs as well as assumptions about future events.  These are subject to risk factors associated with, amongst other things, the economic and business circumstances occurring from time to time in the countries and sectors in which G&H operates.  It is believed that the expectations reflected in these statements are reasonable but they may be affected by a wide range of variables which could cause actual results, and G&H's plans and objectives, to differ materially from those currently anticipated or implied in the forward-looking statements.  Investors should not place undue reliance on any such statements. Nothing in this announcement should be construed as a profit forecast.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTFLFLRISLDIIS]]>
TwitterFacebookLinkedIn